First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial

The purpose of our study was to compare progression-free survival and quality of life (QOL) after cisplatin–gemcitabine (CG) or epirubicin–gemcitabine (EG) in chemotherapy-naive patients with unresectable non-small-cell lung cancer. Patients (n=240) were randomised to receive gemcitabine 1125 mg m(−...

Descripción completa

Detalles Bibliográficos
Autores principales: Wachters, F M, van Putten, J W G, Kramer, H, Erjavec, Z, Eppinga, P, Strijbos, J H, de Leede, G P J, Boezen, H M, de Vries, E G E, Groen, H J M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394313/
https://www.ncbi.nlm.nih.gov/pubmed/14520444
http://dx.doi.org/10.1038/sj.bjc.6601283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394313/
https://www.ncbi.nlm.nih.gov/pubmed/14520444
http://dx.doi.org/10.1038/sj.bjc.6601283

Ejemplares similares